GenMark Gets a Buy Rating from BTIG

By Carrie Williams

In a report released today, Karen Koski from BTIG assigned a Buy rating to GenMark (NASDAQ: GNMK), with a price target of $13. The company’s shares opened today at $9.39.

Koski has an average return of 19.7% when recommending GenMark.

According to TipRanks.com, Koski is ranked #1077 out of 4629 analysts.

GenMark has an analyst consensus of Strong Buy, with a price target consensus of $14.88.

The company has a one year high of $13.67 and a one year low of $8.03. Currently, GenMark has an average volume of 435.1K.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GenMark Diagnostics, Inc. is a molecular diagnostics company. The firm focuses on the development and commercializing of its its proprietary eSensor detection technology. It also manufactures, sells, and supports instruments and molecular tests. The company was founded by Jon Faiz Kayyem on February 12, 2010 and is headquartered in Carlsbad, CA.